Advertisement

Traitement symptomatique

Chapter
  • 760 Downloads

Résumé

Déf.: Triade symptomatique: anorexie (perte d’appétit), nausées et vomissement: effets indésirables les plus couramment expérimentés par les patients après un traitement par cytostatiques.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Réf.

  1. 1.
    ESMO Guidelines Working Group. Chemotherapy-induced nausea and vomiting: ESMO Clinical Recommendations for prophylaxis. Ann Oncol 2007;18(suppl 2):ii83–ii85Google Scholar
  2. 2.
    Grunberg SM, Deuson RR, Mavros P et al. Incidence of chemotherapy-induced nausea and emesis after modern anti-emetics. Cancer 2004;100:2261–2268PubMedGoogle Scholar
  3. 3.
    Hesketh PJ, Kris MG, Grünberg SM et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997;15:103–109PubMedGoogle Scholar
  4. 4.
    Jordan K, Kasper C, Schmoll HJ. Chemotherapy-induced nausea and vomiting: current and new standards in the antiemetic prophylaxis and treatment. Eur J Cancer 2005;41:199–205PubMedGoogle Scholar
  5. 5.
    Kris MG, Heskett PJ, Somerfield MR et al. ASCO Guideline for antiemetics in oncology. J Clin Oncol 2006;24:2932–2947PubMedGoogle Scholar
  6. 6.
    Oettle H, Riess H. Treatment of chemotherapy-induced nausea and vomiting. J Cancer Res Clin Oncol 2001;127:340–534PubMedGoogle Scholar
  7. 7.
    Schnell FM. Chemotherapy-induced nausea and vomiting: the importance of acute antiemetic control. Oncologist 2003;8:187–198PubMedGoogle Scholar

Réf.

  1. 1.
    Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 2004;100:228–237PubMedGoogle Scholar
  2. 2.
    De Pauw BE. Strategies in the treatment of infections in neutropenic patients. Med Microbiol Lett 1996;5:305–309Google Scholar
  3. 3.
    Hughes WT, Armstrong D, Bodey GP et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730–751PubMedGoogle Scholar
  4. 4.
    Kern WV, Cometta A, De Bock R et al. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. N Engl J Med 1999;341:312–318PubMedGoogle Scholar
  5. 5.
    Neuburger S, Maschmeyer G. Update on managment of infections in cancer and stem cell transplant patients. Ann Hematol 2006;85:345–356PubMedGoogle Scholar
  6. 6.
    Pizo PA. Fever in immunocompromised patients. N Engl J Med 1999;341:893–900Google Scholar
  7. 7.
    Smith TJ, Khatcheressiaan J, Lyman GH et al. 2006 Update of recommendations for the use of white blood cell growth factors. An evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187–3205PubMedGoogle Scholar

Réf.

  1. 1.
    Aapro MS. Cameron DA, Pettengell R et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 2006;42:2433–2453PubMedGoogle Scholar
  2. 2.
    Bokemeyer M, Aapro MS, Courdia A et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 2007;43:258–270PubMedGoogle Scholar
  3. 3.
    Clark OAC, Lyman GH, Castro AA et al. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a metaanalysis of randomised controlled trials. J Clin Oncol 2005;23:4198–4214PubMedGoogle Scholar
  4. 4.
    Crawford J et al. Myeloid growth factors in cancer treatment. NCCN, Clinical Practice Guidelines in Oncology-v.2.2005Google Scholar
  5. 5.
    ESMO Guidelines Working Group. Hematopoietic growth factors: ESMO recommendations for the application. Ann Oncol 2007;18(suppl 2):ii89–91Google Scholar
  6. 6.
    ESMO Guidelines Working Group. Erythropoietins in cancer patients: ESMO recommendations for use. Ann Oncol 2007;18(suppl 2):ii86–ii88Google Scholar
  7. 7.
    Rizzo JD, Somerfield MR, Hagerty KL et al. Use of epoetin and darbepoetin in patients with cancer: 2007 ASCO/ASH Clinical Practice Guideline Update. J Clin Oncol 2008;26:132–149PubMedGoogle Scholar
  8. 8.
    Smith TJ, Khatcheressian J, Lyman GH et al. 2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: an evidence-based clinical practice guideline. J Clin Oncol 2005;24:3187–3205Google Scholar
  9. 9.
    Spielberger R, Stiff P, Bensinger W et al. Palifermin for oral mucositis after intensive therapy for hematologic cancer. N Engl J Med 2004;351:2590–2598PubMedGoogle Scholar

Réf.

  1. 1.
    Arends J, Bodoky G, Bozzetti F et. al. ESPEN guidelines on enteral nutrition: non-surgical oncology. Clin Nutr 2006;25:245–259PubMedGoogle Scholar
  2. 2.
    Davis MP, Dreicer R, Walsh D et al. Appetite and cancer associated anorexia. J Clin Oncol 2004;22:1510–1517PubMedGoogle Scholar
  3. 3.
    Detsky A, Mc Laughlin J. Baker J et al. What is Subjective Global Assessment of Nutritional Status? JPEN 1987;11:8–13Google Scholar
  4. 4.
    Doyle C, Kushi LH, Byers T et al. Nutrition and physical activity during and after cancer treatment. CA Cancer J Clin 2006;56:323–353PubMedGoogle Scholar
  5. 5.
    Morrison G, Hark L. Medical Nutrition and Disease. Blackwell Science, 1999Google Scholar
  6. 6.
    Nitenberg G, Raynard B. Nutritional support of the cancer patient: issues and dilemmas. Crit Rev Hematol Oncol 2000;34:137–168Google Scholar
  7. 7.
    Skipworth R, Fearon KCK. The scientific rationale for otimizing nutritional support in cancer. Eur J Gastroenterol Hepatol 2007;19:371–377PubMedGoogle Scholar

Réf.

  1. 1.
    ASPEN: Board of directors. Specific guidelines for disease adults: Cancer JPEN 2002;26:82SA–83SAGoogle Scholar
  2. 2.
    ASPEN: Board of directors. Specific guidelines for disease adults: Cancer — hematopoietic cell transplantation. JPEN 2002;26:83SA–85SAGoogle Scholar
  3. 3.
    Bozetti F, Cavazzi C, Mariani L et al. Artificial nutrition in cancer patients: which route, what composition? World J Surg 1999;23:577–583Google Scholar
  4. 4.
    Wilson RL. Optimizing nutrition for patients with cancer. Clin J Oncol Nurs 2000;4:23–28PubMedGoogle Scholar

Réf.

  1. 1.
    Goldberg GR, Morrison RS. Pain management in hospitalized cancer patients. J Clin Oncol 2007;25:1792–1801PubMedGoogle Scholar
  2. 2.
    Jost LM. Management of cancer pain. ESMO Clinical Recommendations. Ann Oncol 2007;18(suppl 2):ii92–ii94PubMedGoogle Scholar
  3. 3.
    Levy MH, Samuel TA. Management of cancer pain. Semin Oncol 2005;32:179–193PubMedGoogle Scholar
  4. 4.
    McNicol E, Strassels S, Goudas L et al. Nonsteroidal anti-inflammatory drugs, alone or in combination with opioids, for cancer pain: a systematic review. J Clin Oncol 2004;22:1975–1992PubMedGoogle Scholar
  5. 5.
    McQuay H. Opioids in pain management. Lancet 1999;353:2229–2232PubMedGoogle Scholar
  6. 6.
    Mercadante S. The use of anti-inflammatory drugs in cancer pain. Cancer Treat Rev 2001;27:51–61PubMedGoogle Scholar
  7. 7.
    Van den Beuken-Van Everdingen MHJ, De Rijke JM, Kessels AG et al. Prevalence of pain in patients with cancer. Ann Oncol 2007;18:1437–1449PubMedGoogle Scholar

Réf.

  1. 1.
    Carrol KK, Kohli S, Mustian KM et al. Pharmacologic treatment of cancer-related fatigue. Oncologist 2007;12(suppl 1):43–52Google Scholar
  2. 2.
    Escalante CP. Treatment of cancer-related fatigue: an update. Support Care Cancer 2003;11:79–83PubMedGoogle Scholar
  3. 3.
    Glaus A. Fatigue in Patients with Cancer. Analysis and Assessment. Springer, Berlin Heidelberg New York, 1998Google Scholar
  4. 4.
    Iop A, Manfredi AM, Bonura S. Fatigue in cancer patients receiving chemotherapy. Ann Oncol 2004;15:712–720PubMedGoogle Scholar
  5. 5.
    Morrow GR, Shelke AR, Roscoe JA et al. Management of cancer-related fatigue. Cancer Invest 2005;22:229–239Google Scholar
  6. 6.
    Stasi R, Abriani L, Beccaglia P et al. Cancer-related fatigue. Cancer 2003;98:1786–1801PubMedGoogle Scholar
  7. 7.
    Wagner LI, Cella D. Fatigue and cancer: causes, prevalence and treatment approaches. Br J Cancer 2004;91:822–828PubMedGoogle Scholar

Réf.

  1. 1.
    Berenson JR, Hillner BE, Kyle RA et al. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 2002;20:3719–3736PubMedGoogle Scholar
  2. 2.
    Clézardin P, Ebetino FH, Fournier PGJ. Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity. Cancer Res 2005;65:4971–4974PubMedGoogle Scholar
  3. 3.
    Coleman RE. Bisphosphonates in breast cancer. Ann Oncol 2005;16:687–695PubMedGoogle Scholar
  4. 4.
    Hillner BE, Ingle JN, Chlebowski RT et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003;21:4042–4057PubMedGoogle Scholar
  5. 5.
    Lüftner D, Henschke P, Possinger K. Clinical value of bisphosphonates in cancer therapy. Anticancer Res 2007;27:1759–1768PubMedGoogle Scholar
  6. 6.
    Santini D, Vespasiani Gentilucci U, Vincenzi B et al. The antineoplastic role of bisphosphonates: from basic research to clinical evidence. Ann Oncol 2003;14:1468–1476PubMedGoogle Scholar
  7. 7.
    Wu S, Dahut WL, Gulley, JL. The use of bisphosphonates in cancer patients. Acta Oncol 2007;46:581–591PubMedGoogle Scholar

Réf.

  1. 1.
    Convey AM. Management of malignant pleural effusions and ascites. J Support Oncol 2005;3:169–176Google Scholar
  2. 2.
    Nelson KA, Walsh D, Abdullah O et al. Common complications of advanced cancer. Semin Oncol 2000;27:34–44PubMedGoogle Scholar

Réf.

  1. 1.
    Alexandrakis MG, Passam FH, Kyriakou DS et al. Pleural effusions in hematologic malignancies. Chest 2004;125:1546–1555PubMedGoogle Scholar
  2. 2.
    Antony VB, Loddenkemper R, Astoul P et al. Management of malignant pleural effusions. Eur Respir J 2001;18:402–419PubMedGoogle Scholar
  3. 3.
    Antunes G, Neville E, Duffy J et al. BTS guidelines for the management of malignant pleural effusions. Thorax 2003;58:29–38Google Scholar
  4. 4.
    Light RW. Pleural effusion. N Engl J Med 2002;346:1971–1977PubMedGoogle Scholar
  5. 5.
    Pollak JS. Malignant pleural effusions: treatment with tunneled long-term drainage catheters. Curr Opin Pulm Med 2002;8:302–307PubMedGoogle Scholar
  6. 6.
    Rahman NM, Chapman SJ, Davies RJ. Pleural effusion: a structured approach to care. Br Med Bull 2005;72:31–47PubMedGoogle Scholar
  7. 7.
    Tarn AC, Lapworth R. Biochemical analysis of pleural analysis of pleural fluid: what should we measure? Ann Clin Biochem 2001;38:311–322PubMedGoogle Scholar
  8. 8.
    Tassi GF, Cardillo G, Marchetti GP et al. Diagnostic and therapeutical management of malignant pleural effusion. Ann Oncol 2006;17(suppl 2):ii11–ii12Google Scholar

Réf.

  1. 1.
    Chen EP, Miller JI. Modern approaches and use of surgical treatment for pericardial disease. Curr Cardiol Rep 2002;41:4–6Google Scholar
  2. 2.
    Keefe DL. Cardiovascular emergencies in the cancer patient. Semin Oncol 2000;27:244–255PubMedGoogle Scholar
  3. 3.
    Maher EA. Pericardial sclerosis as the primary management of malignant pericardial effusion and cardiac tamponade. J Thorac Cardiovasc Surg 1996;112:637–643PubMedGoogle Scholar
  4. 4.
    Maisch B, Sererovic PM, Ristic AD et al. Guidelines on the diagnosis and management of effusions. Eur Soc Cardiol, 2004Google Scholar
  5. 5.
    Martinoni A, Cipolla CM, Civelli M et al. Intrapericardial treatment of neoplastic pericardial effusions. Herz 2000;25:787–793PubMedGoogle Scholar
  6. 6.
    Retter AS. Pericardial disease in the oncology patient. Heart Dis 2002;4:387–391PubMedGoogle Scholar
  7. 7.
    Shepherd FA. Malignant pericardial effusion. Curr Opin Oncol 1997;9:170–174PubMedGoogle Scholar

Réf.

  1. 1.
    Becker G, Galandi D, Blum HE. Malignant ascites: Systematic review and guideline for treatment. Eur J Cancer 2006;42:589–597PubMedGoogle Scholar
  2. 2.
    Jeffery J, Murphy MJ. Ascitic fluid analysis: the role of biochemistry and haematology. Hosp Med 2001;62:282–286PubMedGoogle Scholar
  3. 3.
    Markmann M. Intraperitoneal chemotherapy. Semin Oncol 1991;18:248–254Google Scholar
  4. 4.
    McHutchinson JG. Differential diagnosis of ascites. Semin Liver Dis 1997;17:191–202Google Scholar
  5. 5.
    Parsons SL, Watson SA, Steele RJ. Malignant ascites. Br J Surg 1996;83:6–14PubMedGoogle Scholar
  6. 6.
    Runyon BA. Care of patients with ascites. N Engl J Med 1994;330:337–342PubMedGoogle Scholar
  7. 7.
    Smith EM, Jayson GC. The current and future management of malignant ascites. Clin Oncol 2003;15:59–72Google Scholar

Réf.

  1. 1.
    American Association of Blood Banks, Association Bulletins #97/2 and #02-4Google Scholar
  2. 2.
    BCSH (British Committee for Standards in Hematology). Guidelines for the use of platelet transfusions. Br J Haematol 2003;122:10–23Google Scholar
  3. 3.
    Goodnough LT, Brecher ME, Kantner MH et al. Transfusion medicine. N Engl J Med 1999;340:438–447, 525–33PubMedGoogle Scholar
  4. 4.
    Klein HG, Spahn DR, Carson JL. Red blood cell transfusion in clinical practice. Lancet 2007;370:415–426PubMedGoogle Scholar
  5. 5.
    Stroncek DF, Rebulla P. Platelet transfusions. Lancet 2007;370:427–438PubMedGoogle Scholar
  6. 6.
    Triulzi DJ. Blood Transfusion Therapy: A Physician’s Handbook, 7th edn. AABB Bookstore, 2002Google Scholar
  7. 7.
    Wandt H, Ehninger G, Gallmeier WM. New strategies for prophylactic platelet transfusion in patients with hematologic diseases. The Oncologist 2001;6:446–450PubMedGoogle Scholar

Réf.

  1. 1.
    Farrugia A, Poulis P. Intravenous immunoglobulin: regulatory perspectives on use and supply. Transfus Med 2001;11:63–74PubMedGoogle Scholar
  2. 2.
    Hellstern P, Halbmayer WM, Köhler M et al. Prothrombin complex concentrates: indications, contraindications and risks. Thromb Res 1999;95:S3–6PubMedGoogle Scholar
  3. 3.
    Key NS. Coagulation factor concentrates. Lancet 2007;370:439–448PubMedGoogle Scholar
  4. 4.
    Staudinger T, Frass M, Rintelen C et al. Influence of prothrombin complex concentrates on plasma coagulation in critically ill patients. Intensive CareMed 1999;25:1105–1110Google Scholar

Réf.

  1. 1.
    Anger JT, Gilbert BR, Goldstein M. Cryopreservation of sperm: indications, methods and results. J Urol 2003;170:1079–1084PubMedGoogle Scholar
  2. 2.
    Crockin SL. Legal issues related to parenthood after cancer. J Natl Cancer Inst Monogr 2005;34:111–113PubMedGoogle Scholar
  3. 3.
    Lee SJ, Schover LR, Partridge AH et al. ASCO recommendations on fertility preservation in cancer patients. J Clin Oncol 2006;24:2917–2931PubMedGoogle Scholar
  4. 4.
    Orwig KE, Schlatt S. Cryopreservation and transplantation of spermatogonia and testicular tissue for the preservation of male fertility. J Natl Cancer Inst Monogr 2005;34:51–56PubMedGoogle Scholar
  5. 5.
    Postovsky S, Lightman A, Aminpour D et al. Sperm cryopreservation in adolescents with newly diagnosed cancer. Med Pediatr Oncol 2003;40:355–359PubMedGoogle Scholar
  6. 6.
    Puschek E, Philip PA, Jeyendran RS. Male fertility preservation and cancer treatment. Cancer Treat Rev 2004;30:173–180Google Scholar
  7. 7.
    Wallace WH, Anderson RA, Irvine DS. Fertility preservation for young patients with cancer: who is at risk and what can be offered? Lancet Oncol 2005;6:209–218PubMedGoogle Scholar

Réf.

  1. 1.
    Falcone T, Bedaiwy MA. Fertility preservation and pregnancy outcome after malignancy. Curr Opin Obstet Gynecol 2005;17:21–26PubMedGoogle Scholar
  2. 2.
    Lee SJ, Schover LR, Partridge AH et al. ASCO recommendations on fertility preservation in cancer patients. J Clin Oncol 2006;24:2917–2931PubMedGoogle Scholar
  3. 3.
    Patrizio P, Butts S, Caplan A. Ovarian tissue preservation and future fertility: emerging technologies and ethical considerations. J Natl Cancer Inst Monogr 2005;34:107–110PubMedGoogle Scholar
  4. 4.
    Practice Committee of the American Society for Reproductive Medicine. Ovarian tissue and oocyte cryopreservation. Fertil Steril 2004;82:933–938Google Scholar
  5. 5.
    Roberts JE, Oktay K. Fertility preservation: a comprehensive approach to the young woman with cancer. J Natl Cancer Inst Monogr 2005;34:57–59PubMedGoogle Scholar

Réf.

  1. 1.
    Basson R, Schultz WW. Sexual sequelae of general medical disorders. Lancet 2007;369:409–424PubMedGoogle Scholar
  2. 2.
    Derogatis LR, Kourlesis SM. An approach to evaluation of sexual problems in the cancer patient. CA Cancer J Clin 1981;31:46–50PubMedGoogle Scholar
  3. 3.
    Hollenbeck BK, Dunn RL, Wei JT et al. Sexual health recovery after prostatectomy, external radiation, or brachytherapy for early stage breast cancer. Curr Urol Rep 2994;5:212–219Google Scholar
  4. 4.
    Kornblith AB, Ligibel J. Psychosocial and sexual functioning of survivors of breast cancer. Semin Oncol 2003;30:799–913PubMedGoogle Scholar
  5. 5.
    Lue TF. Erectile dysfunction. N Engl J Med 2000;342:1802–1813PubMedGoogle Scholar
  6. 5.
    Wilmoth MC, Botchway P. Psychosexual implications of breast and gynecologic cancer. Cancer Invest 1999;17:631–636PubMedGoogle Scholar

Réf.

  1. 1.
    Dimeo F, Stieglitz RD, Novelli-Fischer U et al. Effects of physical activity on the fatigue and psychologic status of cancer patients during chemotherapy. Cancer 1999;85:2273–2277PubMedGoogle Scholar
  2. 2.
    Knols R, Aaronson NK, Uebelhart D et al. Physical exercise in cancer patients during and after medical treatment. J Clin Oncol 2005;23:3830–3842PubMedGoogle Scholar
  3. 3.
    McTiernan A. Physical activity after cancer: physiologic outcomes. Cancer Invest 2004;22:68–81PubMedGoogle Scholar
  4. 4.
    Meyerhardt JA, Heseltine D, Niedzwiecki D et al. Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer. J Clin Oncol 2006;24:3535–3541PubMedGoogle Scholar
  5. 5.
    Stevinson C, Lawlor DA, Fox KR. Exercise interventions for cancer patients. Cancer Causes Control 2004;15:1035–1056PubMedGoogle Scholar

Réf.

  1. 1.
    Keefe DM, Schubert MM, Elting LS et al. Updated clinical practice guidelines for prevention and treatment of mucositis. Cancer 2007;109:820–831PubMedGoogle Scholar
  2. 2.
    Stevenson J, Abernethy P A, Miller C, Currow DC. Managing comorbidities in patients at the end of life. BMJ 2004;329;909–912PubMedGoogle Scholar

Réf.

  1. 1.
    Faller H, Bülzebruck H. Coping and survival in lung cancer: a 10-year follow-up-Am J Psychiatry 2002;159:2105–2107PubMedGoogle Scholar
  2. 2.
    Fawzy FI, Fawzy NW. A structured psychoeducational intervention for cancer patients. Gen Hosp Psychiatry 1994;16:149–192PubMedGoogle Scholar
  3. 3.
    Fritzsche K, Stein B, Herzog T et al. Psychosocial care of oncological in-patients. An empirical study of psychiatric and psychosomatic consultation services. Onkologie 1998;21:150–155Google Scholar
  4. 4.
    Greer S, Moorey S, Baruch JD, Watson M, Robertson BM, Mason A, Rowden L, Law MG, Bliss JM. Adjuvant psychological therapy for patients with cancer: a prospective randomised trial. Br Med J 1992;304:675–680Google Scholar
  5. 5.
    Jenkins V, Fallowfield L, Saul J. Information need of patients with cancer: results from a large study in UK cancer centres. Br J Cancer 2001;84:48–51PubMedGoogle Scholar
  6. 6.
    Kendall WS. Suicide and cancer: a gender-comparative study. Ann Oncol 2007;18:381–387Google Scholar

Réf.

  1. 1.
    Cheville AL. Cancer rehabilitation. Semin Oncol 2005;32:219–224PubMedGoogle Scholar
  2. 2.
    World Health Organization (WHO) 2001. International Classification of Functioning, Disability and Health (ICF). WHO Publication, GenevaGoogle Scholar

Copyright information

© Springer-Verlag France, Paris 2011

Authors and Affiliations

There are no affiliations available

Personalised recommendations